Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × LY-2157299 × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 2 Rectal Neoplasms 1 Prostatic Neoplasms 1 Nasopharyngeal Carcinoma 1 Glioblastoma 1 Camurati-Engelmann Syndrome 1

Interventions

Temozolomide 154 Bevacizumab 88 Radiotherapy 75 Radiation 23 Magnetic Resonance Spectroscopy 23 Lomustine 18 Irinotecan 18 pembrolizumab 17 Surgical Procedures, Operative 16 Carmustine 16 Erlotinib Hydrochloride 12 Nivolumab 11 Specimen Handling 10 Aminolevulinic Acid 10 sargramostim 9 Thalidomide 9 Chemotherapy, Adjuvant 9 Carboplatin 9 Immunoglobulin G 7 Filgrastim 7 Etoposide 7 Drug Therapy 7 Disulfides 7 Cilengitide 7 Sunitinib 6 Sorafenib 6 O(6)-benzylguanine 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01582269 2025-11-24

A Study in Recurrent Glioblastoma (GB)

Eli Lilly and Company

Phase 2 Completed

158 enrolled 20 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡